DrugPatentWatch Database Preview

VIBATIV Drug Profile

« Back to Dashboard

When do Vibativ patents expire, and what generic alternatives are available?

Vibativ is a drug marketed by Theravance Biopharma and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and twenty-four patent family members in thirty-five countries.

The generic ingredient in VIBATIV is telavancin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the telavancin hydrochloride profile page.

Summary for VIBATIV

International Patents:	124
US Patents:	11
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	10
Clinical Trials:	13
Patent Applications:	2
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for VIBATIV
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIBATIV
DailyMed Link:	VIBATIV at DailyMed

Generic Entry Opportunity Date for VIBATIV

NDA:

022110

Dosage:

POWDER;IV (INFUSION)

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VIBATIV

Ingredient-type	Lipoglycopeptides
Drug Class	Lipoglycopeptide Antibacterial

Synonyms for VIBATIV

0701472ZG0

372151-71-8

560130-42-9

AC1MIWRX

AM006875

Arbelic

CHEBI:71226

CHEBI:71229

CHEMBL3301680

CHEMBL507870

D02IJB

D06057

D0B9JO

DB06402

HSDB 8194

LS-192933

N(3'')-[2-(decylamino)ethyl]-29-{[(phosphonomethyl)amino]methyl}vancomycin

SCHEMBL8287015

SIB-1533A

T-1455

Td 6424

TD-6424

Telavancin

Telavancin [INN]

Telavancin HCl

Telavancin Hydrochloride

Telavancin hydrochloride (USAN)

Telavancin hydrochloride [USAN]

Telavancin, Antibiotic for Culture Media Use Only

telavancina

telavancine

telavancinum

UNII-0701472ZG0

UNII-XK134822Z0

Vancomycin, N3'-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride

Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-

Vibativ (TN)

XK134822Z0

US Patents and Regulatory Information for VIBATIV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No			Y	Y
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes			Y
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No			Y
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No

International Patents for VIBATIV

Country	Document Number	Estimated Expiration
European Patent Office	1678201
Spain	2316445
New Zealand	522279
Ukraine	75083

Supplementary Protection Certificates for VIBATIV

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
7	Finland
/2011	Austria		PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
C0051	France		PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
2012002,C1292612	Lithuania		PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902